alprazolam has been researched along with Neuroleptic Malignant Syndrome in 2 studies
Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)
alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.
Neuroleptic Malignant Syndrome: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment." | 5.33 | Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam. ( Fujita, K; Ichihashi, K; Inoue, K; Okazaki, Y; Tanii, H, 2006) |
| "This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment." | 1.33 | Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam. ( Fujita, K; Ichihashi, K; Inoue, K; Okazaki, Y; Tanii, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tanii, H | 1 |
| Ichihashi, K | 1 |
| Inoue, K | 1 |
| Fujita, K | 1 |
| Okazaki, Y | 1 |
| Burch, EA | 1 |
| Downs, J | 1 |
2 other studies available for alprazolam and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.
Topics: Aged; Alprazolam; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Therapy, Combi | 2006 |
Development of neuroleptic malignant syndrome during simultaneous amoxapine treatment and alprazolam discontinuation.
Topics: Alprazolam; Amoxapine; Dibenzoxazepines; Female; Humans; Male; Middle Aged; Neuroleptic Malignant Sy | 1987 |